fashion -WSS

fashion

author：focus 2025-10-02 21:36:10 - browse：289

FogPharma CEO Mathai Mammen Venrock

SAN FRANCISCO — Six months into his tenure as CEO of cancer startup FogPharma, Mathai Mammen is taking the stage at the Westin St. Francis Tuesday for what he’s calling a “big unveil” of how he’s reshaping the biotech. And he’s prepared to go against the grain.

Perhaps the most important thing he’s telling investors at the J.P. Morgan Healthcare Conference is that he plans to eventually pursue a rare Series E round, rather than an IPO or seeking out acquisition offers.

FogPharma last raised money in November 2022, and will need more cash to bring its lead drug past its ongoing Phase 1/2 trial. Most other biotechs in this position are anxiously eyeing the capital markets, hoping that conditions improve and make an IPO more feasible. But Mammen doesn’t see the point, at this stage. “There’s no reason to be a public company. I don’t know why you’d want to be, really,” he told STAT ahead of FogPharma’s presentation.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Wildfire smoke exposes gaps in outdoor worker protections
Next article： Rare Northern Lights show in US this week: Where and how to see it

focus

WSS

Hottest summer in 2,000 years puts focus on extreme heat, health

Abbott's new stent may help patients with peripheral artery disease

Raw milk easy to obtain despite bird flu warning, FDA interstate ban

How redistricting in 6 states could affect who controls Congress

What could happen if Russia blows up the Zaporizhzhia Nuclear Power Plant?

How corporate America is slashing DEI workers amid backlash to diversity programs

focus

fashion

entertainment

Cancer drug shortages should be causing more outrage

The White House hikes tariffs on plastic syringes made in China

Novavax promises a turnaround & Lilly roils the obesity market

Submersible on Titanic tour reported missing off Newfoundland with 5 people aboard

BioMarin wins approval for gene therapy to treat hemophilia A

How corporate America is slashing DEI workers amid backlash to diversity programs

BioMarin wins approval for gene therapy to treat hemophilia A

What a koala virus tells us about the human genome

Sports medicine is finally prioritizing gender equality

Another man arrested in connection with shooting at Kansas nightclub

entertainment

North Korean leader's powerful sister says warplanes repelled US spy plane

Abbott's new stent may help patients with peripheral artery disease

Titanic submersible: What a 'catastrophic implosion' means and what officials found

Adam's Biotech Scorecard: PDS Biotech's survival benefit is overstated

Ahead of NATO summit, Biden meets with King Charles for 1st time since coronation

How corporate America is slashing DEI workers amid backlash to diversity programs

focus

leisure time

Wikipedia

leisure time